Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

17.09
-0.8300-4.63%
Post-market: 17.380.2902+1.70%19:57 EDT
Volume:1.22M
Turnover:20.93M
Market Cap:1.06B
PE:-4.94
High:17.92
Open:17.92
Low:16.81
Close:17.92
52wk High:71.50
52wk Low:8.73
Shares:62.29M
Float Shares:40.64M
Volume Ratio:0.68
T/O Rate:3.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4602
EPS(LYR):-3.4602
ROE:-207.10%
ROA:-16.21%
PB:5.35
PE(LYR):-4.94

Loading ...

How Early AMT-191 Gene Therapy Signals Will Impact uniQure (QURE) Investors

Simply Wall St.
·
Feb 09

Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch

Benzinga_recent_news
·
Feb 07

uniQure präsentiert neue Phase-I/IIa-Daten zur Gentherapie AMT-191 bei Fabry-Krankheit

Reuters
·
Feb 06

uniQure Reports Sustained Enzyme Increases in Phase I/IIa Fabry Disease Gene Therapy Trial

Reuters
·
Feb 06

A Look At uniQure (QURE) Valuation After FDA Setback And Legal Investigations

Simply Wall St.
·
Feb 04

uniQure Initiated at Equal-Weight by Barclays

Dow Jones
·
Jan 28

Barclays Initiates Coverage on uniQure N.V With Equal Weight Rating, $31 Price Target

MT Newswires Live
·
Jan 28

uniQure initiated with an Equal Weight at Barclays

TIPRANKS
·
Jan 28

uniQure NV Director Robert Gut Reports Disposal of Common Shares

Reuters
·
Jan 15

uniQure Showcases Gene Therapy Leadership and Pipeline Progress in New Corporate Presentation

Reuters
·
Jan 13

uniQure NV Director Jack Kaye Reports Disposal of Common Shares

Reuters
·
Jan 13

uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway

Benzinga
·
Jan 10

US-Listed Shares of Uniqure Rise 13% Premarket as FDA Review Talks Revive Hopes for Huntington's Therapy

THOMSON REUTERS
·
Jan 09

BUZZ-UniQure rises as US FDA review talks revive hopes for Huntington's therapy

Reuters
·
Jan 09

uniQure announces Type A meeting scheduled with FDA

TIPRANKS
·
Jan 09

Does uniQure (QURE) FDA Feedback on AMT-130 Reframe Its Risk, Funding and Strategy Profile?

Simply Wall St.
·
Dec 18, 2025

uniQure call volume above normal and directionally bullish

TIPRANKS
·
Dec 17, 2025

What's Going On With uniQure Stock On Tuesday?

Benzinga
·
Dec 17, 2025

uniQure Is Maintained at Buy by Chardan Capital

Dow Jones
·
Dec 05, 2025

Why uniQure Stock Is Trading Lower After FDA Meeting Update

Benzinga_recent_news
·
Dec 05, 2025